Atrial Fibrillation

Overview & Definition

Atrial fibrillation (AF) is a supraventricular tachyarrhythmia defined by uncoordinated atrial electrical activation with consequent loss of effective atrial mechanical contraction. In place of the single organised sinus impulse that normally propagates across both atria each cycle, AF is a storm of chaotic depolarisation waves — the atria quiver rather than contract, and the ventricles respond to a rapid, unpredictable barrage of impulses conducted through the atrioventricular (AV) node. [1]

The diagnosis rests on three ECG hallmarks that every candidate must be able to recite verbatim:[1]

1. An irregularly irregular ventricular (RR) rhythm — no pattern to the spacing between beats.
2. Absent P waves — no discrete atrial depolarisation is visible.
3. Fibrillatory f-waves — fine, rapid, low-amplitude undulations of the baseline (best seen in lead V1) replacing organised atrial activity, at a rate of 350 to 600 per minute. [1]

When the f-waves are coarse (amplitude greater than 0.5 mm in V1) the rhythm can superficially resemble atrial flutter; the decisive discriminator is the absolute irregularity of the RR intervals in AF, contrasted with the regular (or regularly irregular) ventricular response of flutter. [1]

The term "lone AF" — formerly used for AF in younger patients with no identifiable cause — is now discouraged: with modern imaging and risk-factor assessment, virtually all patients have an identifiable driver (most often hypertension, sleep-disordered breathing, or subclinical cardiomyopathy).[1]

Classification

AF is classified by its temporal pattern, not by ventricular rate or symptom burden. The thresholds are examiner favourites because they govern decisions about rhythm-versus-rate strategy. [1]

Note that mild mitral regurgitation of degenerative origin, bioprosthetic valves without other risk, and mitral valve repair do not by themselves qualify as "valvular AF" in the contemporary sense — these patients are managed with DOACs. The defining lesion is rheumatic mitral stenosis or a mechanical valve. [1]

Epidemiology & Risk Factors

AF is the commonest sustained cardiac arrhythmia and one of the few cardiovascular epidemics still growing in absolute numbers, driven by ageing populations and the global rise in obesity, hypertension, and diabetes. Key figures a candidate should hold: [1]

Hypertension is the commonest single driver of AF, present in over 70% of patients. The full list of modifiable and cardiac risk factors is recalled by the high-yield mnemonic HIPAT-H: [1]

Beyond HIPAT-H, recognise obesity (dose-response with AF incidence and recurrence after ablation), diabetes, valvular and rheumatic heart disease (dominant cause in the Indian subcontinent), pericarditis and myocarditis, post-cardiac-surgery state (30–40% of coronary bypass and valve patients), endurance-athlete remodelling, and genetic predisition (family history doubles risk).[1]

The complication burden is what makes AF dangerous — the arrhythmia itself is rarely the immediate cause of death. The four cardinal complications are: ischaemic stroke and systemic thromboembolism (typically a large, severe cardioembolic stroke with high disability and mortality), heart failure (both a cause and a consequence — uncontrolled ventricular rate produces a potentially reversible tachycardia-induced cardiomyopathy), cognitive decline and dementia (linked to silent cerebral micro-infarcts), and roughly doubled all-cause mortality.[1]

Pathophysiology

AF is sustained by two overlapping and synergistic mechanisms. Understanding both is what makes the rationale for ablation intuitive. [1]

1. Focal triggers. In many patients — particularly those with paroxysmal AF — the arrhythmia is initiated by rapidly firing ectopic foci, most of which arise from the muscular sleeves of myocardial tissue extending 1–3 cm into the pulmonary veins where they join the left atrium. These sleeves possess intrinsic automaticity and can generate the rapid bursts that trigger AF. The therapeutic implication is direct: electrically isolating the pulmonary veins from the left atrium (pulmonary vein isolation, PVI) removes the trigger and is the cornerstone of catheter ablation.[1]

2. Multiple re-entrant wavelets. Once initiated, AF is sustained by multiple chaotic re-entrant wavelets circulating through atrial tissue. The substrate for re-entry is heterogeneous conduction and shortened, dispersed refractory periods — a function of atrial dilation, fibrosis, and the myopathy of long-standing AF. The older multiple-wavelet hypothesis (Moe, refined by Allessie) explains why AF begets AF: each episode shortens atrial refractoriness and promotes fibrosis, lowering the threshold for the next episode and making termination harder. [1]

Electrical and structural remodelling is the molecular substrate for the "AF begets AF" adage. Within days of sustained AF, atrial myocytes down-regulate the L-type calcium current and up-regulate inward-rectifier potassium currents, shortening the action potential duration and effective refractory period — exactly the change that favours more re-entry. Over months to years, fibrosis, fatty infiltration, and atrial dilation further disrupt conduction, which is why early rhythm control (EAST-AFNET 4) and aggressive risk-factor modification (weight loss, blood-pressure control, sleep-apnoea treatment) are increasingly emphasised.[3][1]

The irregularly irregular ventricular response is the bedside signature of AF and a direct mechanical consequence of the chaotic atrial rhythm. The AV node is bombarded by 350–600 atrial depolarisations per minute but conducts only a variable, unpredictable subset to the ventricles — governed by concealed conduction, concealed discharge, and refractoriness within the node itself. The result is the diagnostic irregular irregularity of the RR intervals. The ventricular rate in untreated AF is typically 100–160 bpm, but it can be much faster in sympathetic-driven states (sepsis, hyperthyroidism, exercise, post-operative) or deceptively slow when the AV node is diseased or blunted by drugs (beta-blocker, digoxin). [1]

Why AF causes stroke — the mechanism that underpins the entire anticoagulation enterprise. In sinus rhythm, the left atrial appendage (LAA) contracts and empties with each beat. In AF, the atria do not contract effectively; blood stagnates in the LAA, a long, blind-ended, trabeculated pouch where flow is naturally sluggish. Stasis plus endocardial dysfunction and hypercoagulability (the Virchow triad, applied to AF) produces thrombus, which embolises — typically to the brain, producing a large-territory, often devastating, cardioembolic stroke. Over 90% of AF-related thrombus originates in the LAA, which is why anticoagulation and, in selected patients, LAA occlusion (e.g. Watchman device) are the two stroke-prevention strategies.[1]

Clinical Presentation

The presentation of AF spans an enormous spectrum — from the patient who is entirely asymptomatic and discovered at a routine blood-pressure check, to the patient who arrives in cardiogenic shock. [1]

Typical symptoms are driven by the loss of the atrial contribution to filling (the "atrial kick", worth 15–30% of stroke volume), the rapid ventricular rate, and the irregularity: [1]

• Palpitations — classically described as fast and irregular, often coming on abruptly and ceasing suddenly in paroxysmal AF.
• Dyspnoea and reduced exercise tolerance — from loss of atrial kick and tachycardia.
• Fatigue — often the dominant and most under-recognised symptom, especially in the elderly.
• Chest pain — from rapid rate and underlying ischaemia, or from the arrhythmia itself.
• Presyncope or syncope — from rate-related hypotension or, rarely, a sinus pause on termination of paroxysmal AF ("brady-tachy syndrome").
• Polyuria — atrial natriuretic peptide release from the stretched atria (an under-taught but classic clue). [1]

Asymptomatic ("silent") AF is strikingly common — up to one-third of all AF — and is often detected only on an opportunistic pulse check, a routine ECG, a smartwatch, or when a stroke is the first manifestation. A substantial fraction of "cryptogenic" stroke is attributable to undiagnosed paroxysmal AF, which is why prolonged rhythm monitoring (insertable cardiac monitor) is part of the cryptogenic-stroke work-up. [1]

Bedside signs that reward the careful examiner: [1]

• Irregularly irregular pulse — the cardinal sign. Confirm at the radial and the apex.
• Pulse deficit — the apical (heart) rate exceeds the radial (wrist) rate, because some ventricular beats are too weakly contractile (short filling time) to transmit a palpable peripheral pulse. A deficit of more than 10 bpm is clinically significant.
• Variable intensity of the first heart sound (S1) — because the AV filling interval changes beat to beat, altering mitral-valve closure force.
• Absent "a" waves in the jugular venous pulse (JVP) — there is no coordinated atrial contraction to generate the venous "a" wave.
• Signs of an underlying cause: a thyroid goitre or eye signs of thyrotoxicosis, the murmurs of mitral valve disease, crackles and a third heart sound of heart failure, or fever and a septic focus. [1]

Differential Diagnosis

The differential of an irregularly irregular pulse is short, high-yield, and distinguished almost entirely on the ECG: [1]

Pre-excited AF (Wolff-Parkinson-White) is the must-not-miss mimic and the most dangerous trap in AF management. The ECG shows a broad, irregularly irregular tachycardia with delta waves and QRS morphology that varies beat to beat. It can easily be confused with ventricular tachycardia — but VT is essentially always regular, whereas pre-excited AF is irregular. The management is life-critical and distinct: never give AV-nodal blockers (adenosine, verapamil, diltiazem, beta-blocker, or digoxin) — these block the AV node, accelerating conduction down the accessory pathway and risking degeneration to ventricular fibrillation. The correct drugs are intravenous procainamide, ibutilide, or amiodarone, or synchronised DC cardioversion if unstable. [1]

Clinical & Bedside Assessment

The focused assessment of a patient with suspected AF serves three goals: confirm the rhythm, assess haemodynamic stability, and search for an underlying cause. [1]

Confirm the rhythm. Manual pulse palpation reveals an irregularly irregular pulse, and a pulse deficit (apical rate greater than radial) supports the diagnosis. But the pulse is not enough — diagnosis requires objective ECG documentation: a 12-lead ECG, or at minimum a single-lead rhythm strip of at least 30 seconds demonstrating the three hallmarks (absent P waves, f-waves, irregularly irregular RR).[1]

Assess stability. The single most important bedside judgement in AF is whether the patient is haemodynamically unstable — this determines whether the next step is drugs (stable) or electricity (unstable). The four instability criteria are: hypotension (systolic BP under 90 mmHg or signs of shock), acute heart failure (pulmonary oedema, hypoxia), ongoing ischaemic chest pain, or reduced conscious level. Any one mandates emergency synchronised DC cardioversion, not a rate-control drug.[1][2]

Search for a cause. Examine for: thyroid signs (goitre, tremor, eye signs) of thyrotoxicosis; murmurs of valvular disease (especially the rumbling mid-diastolic of mitral stenosis); signs of heart failure (raised JVP, basal crackles, S3, peripheral oedema); signs of sepsis or pneumonia; and stigmata of alcohol excess. Every new AF patient gets thyroid function tests as part of first-line bloods. [1]

Investigations

The first-line work-up for new AF has three aims: confirm the rhythm, find a cause, and assess stroke and bleeding risk to plan anticoagulation. [1]

Ambulatory ECG monitoring is reserved for detecting paroxysmal AF when the resting ECG is normal but suspicion is high (e.g. cryptogenic stroke, unexplained palpitations). Options range from a 24–72 hour Holter monitor, through patient-activated external loop recorders (1–4 weeks), to implantable cardiac monitors / insertable loop recorders (up to 3 years) for the elusive paroxysm — the latter is the most sensitive tool for detecting silent AF after cryptogenic stroke.[1]

Transoesophageal echocardiography (TOE/TEE) has two roles. First, to exclude left atrial appendage thrombus before cardioversion or ablation when the clinician wants to shorten the mandatory 3-week pre-cardioversion anticoagulation window. Second, to assess the severity of valvular lesions suspected on transthoracic echo. A thrombus seen on TOE is an absolute contraindication to cardioversion until it has been treated with anticoagulation and resolved. [1]

CHA2DS2-VASc — stroke-risk score (reproduced verbatim)

CHA2DS2-VASc, reproduced exactly as the examiner expects:[1]

• C — Congestive heart failure / LV dysfunction — 1 point
• H — Hypertension (treated or untreated) — 1 point
• A2 — Age 75 years or older — 2 points
• D — Diabetes mellitus — 1 point
• S2 — Prior stroke, TIA, or systemic thromboembolism — 2 points
• V — Vascular disease (prior MI, peripheral arterial disease, aortic plaque) — 1 point
• A — Age 65–74 years — 1 point
• Sc — Sex category, female — 1 point [1]

Maximum = 9 (men) or 10 (women, with the sex point). Anticoagulate at a score of 2 or more in men or 3 or more in women; consider at 1 in men. Female sex as the sole point (a score of 1 in a woman under 65 with no other risk) does not by itself mandate anticoagulation. Worked example: a 78-year-old woman with hypertension and type 2 diabetes scores 2 (age) + 1 (HTN) + 1 (DM) + 1 (sex) = 5 — anticoagulate. [1]

HAS-BLED — bleeding-risk score (reproduced verbatim)

HAS-BLED is used alongside CHA2DS2-VASc not to decide whether to anticoagulate but to flag correctable bleeding-risk factors:[1]

• H — Hypertension (uncontrolled, systolic over 160 mmHg) — 1 point
• A — Abnormal renal or liver function — 1 point each (max 2)
• S — Prior stroke — 1 point
• B — Prior major bleeding or bleeding predisposition — 1 point
• L — Labile INR (time in therapeutic range under 60%, on warfarin) — 1 point
• E — Elderly (age over 65) — 1 point
• D — Drugs (concurrent antiplatelet or NSAID) or excess alcohol — 1 point each (max 2) [1]

Maximum = 9. A score of 3 or more signals high bleeding risk and prompts closer monitoring, attention to modifiable factors (control the blood pressure, stop the NSAID, reduce alcohol), and preferential use of agents with lower bleeding profiles (apixaban). A high HAS-BLED score is explicitly not a reason to withhold anticoagulation — the stroke risk in AF almost always exceeds the bleeding risk, and the modifiable factors flagged by HAS-BLED should be corrected, not used to deny therapy.[1]

Management — Resuscitation

The immediate, time-critical decision in any patient presenting with AF is whether they are haemodynamically unstable. This single judgement bifurcates the entire pathway and is heavily examined. [1]

[1]

Management — Definitive & Stepwise

Modern AF care is organised around the ABC pathway — a framework adopted by the 2020 ESC guideline and echoed by the 2023 ACC/AHA/ACCP/HRS update and NICE NG196.[1][2]

A — Avoid stroke (anticoagulation)

Anticoagulation is the single most evidence-supported intervention in AF and the largest contributor to survival. Anticoagulate when CHA2DS2-VASc is 2 or more in men, or 3 or more in women; consider at intermediate scores; generally withhold at 0 (men) or 1 (women, sex point alone).[1][2]

For non-valvular AF, a DOAC is preferred over warfarin — DOACs have a more predictable dose response, no routine INR monitoring, fewer food and drug interactions, and equivalent or lower stroke rates with less intracranial bleeding. The four approved DOACs and their pivotal trials: [1]

[1] [1] [1] [1] [1] [1] [1]

Warfarin (target INR 2.0–3.0) is mandatory for valvular AF (mechanical valve or moderate-to-severe mitral stenosis) and remains an option for non-valvular AF where DOACs are unavailable, unaffordable, or contraindicated (e.g. severe renal failure, antiphospholipid syndrome).[1][2]

Left atrial appendage occlusion (e.g. Watchman device) is an option for stroke prevention when long-term anticoagulation is contraindicated (e.g. prior life-threatening bleed) and the patient is at high thromboembolic risk — typically followed by a period of anticoagulation and then dual antiplatelet therapy.[2]

B — Better symptom control (rate or rhythm)

The choice between rate control (leave the patient in AF, control the ventricular response) and rhythm control (try to restore and maintain sinus rhythm) is symptom-driven, not mortality-driven. AFFIRM showed no survival advantage for a routine rhythm-control strategy over rate control.[4]

Rate control is first-line for most patients, especially older patients with mild symptoms and permanent AF. [1]

[1] [1] [1]

Rhythm control is indicated for: (a) symptomatic patients in whom rate control fails to control symptoms, (b) first-episode AF, (c) AF with a treated reversible trigger (e.g. thyrotoxicosis controlled), (d) AF complicating heart failure with reduced ejection fraction (HFrEF) where restoring sinus rhythm may improve cardiac output, and (e) younger patients in whom early rhythm control is favoured by EAST-AFNET 4.[3]

[1] [1] [1]

Electrical cardioversion (synchronised DC shock) restores sinus rhythm in 70–90% when AF onset is recent. The two anticoagulation strategies for elective cardioversion: [1]

1. Conventional (3-and-4 rule): anticoagulate for at least 3 weeks before and at least 4 weeks after cardioversion, regardless of CHA2DS2-VASc score, because the atria remain mechanically "stunned" for weeks after electrical restoration to sinus rhythm.
2. TOE-guided: anticoagulate from presentation, perform TOE to exclude LAA thrombus, cardiovert if clear, then anticoagulate for at least 4 weeks afterwards.[1]

Catheter ablation (pulmonary vein isolation) is the most effective rhythm-control strategy, achieving sinus rhythm in 60–80% of paroxysmal AF and 40–60% of persistent AF after one or more procedures. CABANA showed no overall mortality benefit of ablation over drug therapy in the intention-to-treat analysis, so ablation is symptom- and selection-driven — favoured for symptomatic paroxysmal AF refractory to antiarrhythmics, and increasingly for AF complicating HFrEF (where subgroup analyses suggest benefit).[9][2]

C — Cardiovascular and comorbidity optimisation

Every AF review should address the modifiable drivers that independently predict AF recurrence, progression, and complication burden: [1]

• Treat hypertension to target (under 130/80 mmHg in most).
• Weight loss — each unit of BMI reduction is associated with AF regression (LEGACY and CARDIO-FIT trials).
• Screen and treat obstructive sleep apnoea with CPAP.
• Reduce alcohol to safe limits or abstain.
• Manage diabetes, ischaemic heart disease, and heart failure to guideline targets.
• Address sedentary lifestyle — moderate exercise is protective.[1][2]

Specific Subtypes & Scenarios

Paroxysmal AF — a "pill-in-the-pocket" strategy (single oral dose of flecainide 200 mg or propafenone 600 mg taken at the onset of symptoms, after medical supervision and confirmation of a structurally normal heart) is appropriate for patients with infrequent, well-tolerated episodes. For frequent or bothersome recurrence, catheter ablation (PVI) is superior to antiarrhythmic drugs for maintaining sinus rhythm and is the rhythm-control modality of choice.[2]

AF with rapid ventricular response and haemodynamic compromise — emergency synchronised DC cardioversion. There is no role for rate-control drugs as the first intervention in the unstable patient. [1]

Pre-excited AF (WPW) — broad, irregular tachycardia with delta waves. Never AV-nodal blockers (adenosine, verapamil, diltiazem, beta-blocker, digoxin). Use IV procainamide, ibutilide, or amiodarone, or synchronised cardioversion if unstable. After restoration of sinus rhythm, refer for accessory-pathway ablation.[2]

Post-cardiac-surgery AF — occurs in 30–40% of patients after coronary bypass or valve surgery, typically on day 2–3, and is often self-limiting. Rate control (beta-blocker, with amiodarone for refractory cases or pre-existing LV dysfunction) is first-line. Anticoagulation follows the usual CHA2DS2-VASc-based decision, accounting for post-operative bleeding risk.[1]

AF in HFrEF — beta-blocker for rate control (avoid diltiazem/verapamil as negative inotropes); digoxin or amiodarone for additional rate control. Catheter ablation is particularly favoured — subgroup analyses of CASTLE-AF and the CABANA HFrEF subgroup suggest benefit in survival and LV function. Dronedarone is contraindicated in unstable HF (PALLAS).[9]

Valvular AF (mitral stenosis or mechanical valve) — warfarin only (target INR 2.0–3.0 for mitral stenosis; mechanical-valve target depends on valve position and type, typically 2.5–3.5). DOACs are contraindicated.[1]

AF in hyperthyroidism — treat the underlying thyrotoxicosis (antithyroid drugs, radioiodine, surgery); beta-blocker (propranolol) for rate control; anticoagulate by CHA2DS2-VASc while thyrotoxic, often discontinued once euthyroid and in sinus rhythm. Cardioversion is unlikely to succeed while the patient is thyrotoxic. [1]

Complications & Pitfalls

The classic examiner-loved pitfalls, each of which can maim or kill a patient: [1]

• Giving AV-nodal blockers in pre-excited AF (WPW) — accelerates conduction down the accessory pathway and precipitates VF.
• Using a DOAC in valvular AF (mechanical valve or moderate-severe mitral stenosis) — RE-ALIGN and registries show harm or inferior efficacy; warfarin is mandatory.
• Withholding anticoagulation because the HAS-BLED score is high — HAS-BLED flags correctable risk factors; it does not contraindicate treatment.
• Cardioverting without adequate peri-procedural anticoagulation — the atria are mechanically stunned and the thromboembolic risk is high immediately post-cardioversion.
• Treating the rhythm without addressing the trigger — thyrotoxicosis, sepsis, alcohol, pulmonary embolism, uncontrolled hypertension all need treatment or AF will recur.
• Missing the diagnosis of paroxysmal AF in a cryptogenic stroke — prolonged monitoring (implantable loop recorder) is part of the work-up.
• Assuming an irregular pulse is AF without an ECG — flutter with variable block, MAT, and frequent ectopics can all mimic AF. [1]

Prognosis & Disposition

Prognosis is determined by the same three pillars as management — stroke prevention, symptom control, and comorbidity management. Untreated AF roughly doubles all-cause mortality, mostly via stroke and heart failure; this excess mortality is largely abolished by appropriate anticoagulation, rate/rhythm control, and aggressive risk-factor modification.[1]

The landmark prognosis trials a candidate should hold: [1]

Disposition. Stable, rate-controlled AF is managed as an outpatient — the patient is discharged on oral rate-control medication, anticoagulation if indicated, with primary-care or cardiology follow-up. Admission is warranted for: haemodynamic instability, rapid AF requiring IV rate or rhythm control, new embolic stroke, suspected serious underlying cause (acute MI, decompensated HF, thyrotoxic storm, sepsis), or initiation of complex therapy (e.g. IV amiodarone with monitoring).[1]

Follow-up and safety-net — at each review: confirm anticoagulation adherence (DOAC or INR if warfarin) and re-check CHA2DS2-VASc and HAS-BLED; assess symptom control and recheck heart rate; review renal and hepatic function for dose adjustments; reinforce modifiable risk-factor targets (weight, blood pressure, alcohol, sleep apnoea); and arrange ECG monitoring for paroxysmal AF recurrence. [1]

Special Populations

Heart failure with reduced ejection fraction (HFrEF). The AF–HFrEF relationship is bidirectional and dangerous. Rate control with a beta-blocker is preferred (avoid diltiazem/verapamil as negative inotropes). Digoxin or amiodarone provide additional rate control. Catheter ablation is favoured over antiarrhythmic drugs in HFrEF — CASTLE-AF showed ablation reduced a composite of death and HF hospitalisation in selected HFrEF patients with AF, and is now a class I indication in the 2023 ACC/AHA/ACCP/HRS update for selected HFrEF patients. Dronedarone is contraindicated in unstable HF.[2][9]

The elderly. CHA2DS2-VASc is heavily age-weighted (age 65–74 = 1; age 75+ = 2), so almost all elderly AF patients warrant anticoagulation — and HAS-BLED is also high. Apixaban is often the preferred agent: its dose-reduction criteria (2.5 mg BD if two or more of age 80+, weight 60 kg or under, creatinine 1.5 mg/dL or more) make it safer in the elderly, and ARISTOTLE showed lower major bleeding than warfarin in older subgroups. Falls and frailty are not absolute contraindications — the stroke risk usually exceeds the bleeding risk even when falls are accounted for.[8]

Chronic kidney disease (CKD). DOAC doses must be adjusted by creatinine clearance: [1]

Valvular AF (mitral stenosis or mechanical valve). Warfarin only — DOACs contraindicated (RE-ALIGN for mechanical valves; subgroup data for mitral stenosis).[1]

Pregnancy. Anticoagulation in pregnant AF patients is by low-molecular-weight heparin (e.g. enoxaparin), which does not cross the placenta. Warfarin is teratogenic (especially weeks 6–12) and is avoided until the second trimester in mechanical-valve patients who require it; DOACs are avoided (limited safety data). Rate control with beta-blocker (metoprolol preferred; avoid atenolol due to fetal growth restriction) or digoxin. AF is uncommon in pregnancy and should prompt a search for a precipitant (thyrotoxicosis, anaemia). [1]

Post-cardiac-surgery AF. Common (30–40%), usually transient, peaks day 2–3. Rate control (beta-blocker) first-line; short-course amiodarone for refractory cases or pre-existing LV dysfunction. Anticoagulation follows CHA2DS2-VASc, weighing bleeding risk.[1]

Evidence, Guidelines & Regional Differences

The two governing guidelines, both deeply evidence-based: [1]

• 2020 ESC Guidelines (Hindricks et al., 2021) — introduced the ABC pathway, DOAC-preference framework for non-valvular AF, early rhythm control (echoing EAST-AFNET 4), and aggressive risk-factor modification.[1]
• 2023 ACC/AHA/ACCP/HRS Guideline (Joglar et al., 2024) — broadly concordant with ESC; explicitly endorses DOAC preference, LAA occlusion for selected patients, catheter ablation in HFrEF, and risk-factor modification.[2]

NICE NG196 (UK) is similarly aligned: DOAC preferred for non-valvular AF, ABC pathway, lenient rate control, catheter ablation for drug-refractory symptomatic paroxysmal AF. [1]

[1]

The current controversy is the shift from routine rate control toward early rhythm control (EAST-AFNET 4) and aggressive risk-factor modification (weight, OSA, BP, alcohol) — a paradigm that moves the locus of care upstream, before atrial remodelling is established.[3]

Exam Pearls

• ECG hallmark: irregularly irregular rhythm, absent P waves, f-waves — the commonest sustained arrhythmia.
• CHA2DS2-VASc: age 75+ and prior stroke score 2 each; everything else (CHF, HTN, DM, vascular, age 65–74, female sex) scores 1; anticoagulate at 2 or more in men, 3 or more in women (female sex alone is not enough).
• HAS-BLED 3 or more = high bleeding risk — flags correctable factors, does NOT deny anticoagulation.
• Mechanical valve or moderate-severe mitral stenosis = warfarin only (DOAC contraindicated).
• Pre-excited AF (WPW): broad irregular tachycardia with delta waves; NEVER AV-nodal blockers — procainamide/amiodarone or cardiovert.
• Cardioversion anticoagulation: 3 weeks before AND 4 weeks after (or TOE-guided), regardless of CHA2DS2-VASc.
• Apixaban dose reduction: 2.5 mg BD if two or more of age 80+, weight 60 kg or under, creatinine 1.5 mg/dL or more.
• DOAC reversal: idarucizumab (dabigatran), andexanet alfa (rivaroxaban, apixaban, edoxaban).
• "AF begets AF" — atrial remodelling shortens refractoriness and promotes fibrosis; pulmonary veins are the usual focal trigger (basis for ablation).
• Rate vs rhythm: AFFIRM — no survival advantage for routine rhythm control; EAST-AFNET 4 — early rhythm control improves composite CV outcome; RACE II — lenient rate control (resting HR under 110 bpm) non-inferior to strict; CABANA — ablation is not a default mortality play (symptom-driven; benefit in HFrEF).
• Lenient rate target: resting ventricular rate under 110 bpm in stable permanent AF.
• Pill-in-the-pocket: single-dose flecainide 200 mg (or propafenone 600 mg) for infrequent, well-tolerated paroxysmal AF in a structurally normal heart — always with an AV-nodal blocker on board.
• Tachycardia-induced cardiomyopathy is potentially reversible with rate or rhythm control.
• Polyuria in new AF — atrial natriuretic peptide release (classic exam clue).
• Absent "a" waves in the JVP and variable-intensity S1 are the bedside signs of atrial chaos. [1]

Self-test: A 76-year-old woman with hypertension and diabetes presents with new AF. CHA2DS2-VASc? Anticoagulation?

CHA2DS2-VASc = 2 (age 75+) + 1 (HTN) + 1 (DM) + 1 (age 65–74 not applicable — she is over 75) ... recalculate: age 75+ = 2, HTN = 1, DM = 1, female sex = 1 = 5. Anticoagulate — a DOAC (apixaban 5 mg BD, dose-reduced only if she meets two-of-three criteria) is preferred. HAS-BLED to flag correctable bleeding risk, but a high score does not deny anticoagulation.

[1]

Exam application bank (NEET-PG / INICET)

One-line answer

Atrial fibrillation (AF) is the commonest sustained cardiac arrhythmia: irregularly irregular rhythm, absent P waves, fibrillatory f-waves. Care follows the ABC pathway: Avoid stroke (anticoagulate if CHA2DS2-VASc ≥2 in men, ≥3 in women, with a DOAC preferred), Better symptom control (rate vs rhythm control), Cardiovascular risk-factor optimisation. Unstable AF with rapid ventricular response needs emergency synchronised DC cardioversion.

Worked stems (answer without another resource)

Stem 1 — Classic presentation. Map symptoms to mechanism; name the first investigation and first treatment step with dose/route if drug therapy is standard. [1]

Stem 2 — Unstable / complicated. List red flags that force immediate resuscitation, theatre, ICU, antidote, or reperfusion — and what you do in the first 15 minutes. [1]

Stem 3 — Atypical group. Elderly, pregnancy, child, or immunocompromised: how presentation and thresholds change. [1]

Stem 4 — Differential trap. Name the three closest mimics and one discriminator for each. [1]

Stem 5 — Disposition. Who goes home with safety-netting, who is admitted, who needs HDU/ICU/theatre, and what follow-up is mandatory. [1]

Rapid viva checklist

1. Definition + classification
2. Pathophysiology chain
3. Bedside signs / criteria
4. Score with exact components (if any)
5. Emergency bundle
6. Definitive therapy with doses
7. Complications of disease and of treatment
8. Special populations
9. Guideline/trial name if classic
10. Three exam traps

Coverage self-check

If you cannot answer any stem above from this page alone, re-read the matching section — the page is intended to be self-sufficient for final-prof and NEET-PG/INICET questions on Atrial Fibrillation.

References

1. [1]Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Eur Heart J, 2021.PMID 32860505
2. [2]Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Circulation, 2024.PMID 38033089
3. [3]Kirchhof P, Camm AJ, Goette A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation N Engl J Med, 2020.PMID 32865375
4. [4]Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation N Engl J Med, 2002.PMID 12466506
5. [5]Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation N Engl J Med, 2010.PMID 20231232
6. [6]Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med, 2009.PMID 19717844
7. [7]Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med, 2011.PMID 21830957
8. [8]Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med, 2011.PMID 21870978
9. [9]Packer DL, Mark DB, Robb RA, et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial JAMA, 2019.PMID 30874766